Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Metabolon, Synlab Ink Commercialization Deal for Insulin Resistance Test

Metabolon, Synlab Ink Commercialization Deal for Insulin Resistance Test

Mar 29, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Metabolon announced today that it has signed a deal to commercialize its Quantose IR insulin resistance test in 30 international markets with European clinical laboratory network Synlab.

Quantose IR is a blood-based test uses insulin and three non-glycemic biomarkers to assess the risk of a patient developing prediabetes. Under the terms of the arrangement, Synlab will introduce the test first in Spain and then in other markets throughout Europe, Latin America, and the Middle East during 2016.

Additional terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

P.1 Re-infection Concerns

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

Aiming for May

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

NIH Program to Address Structural Racism

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

PNAS Papers on Myelopathy GWAS in Japan, Hypertrophic Cardiomyopathy, MRSA Methylation

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
17
Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

What's Popular?

In Molecular Diagnostics

  1. Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service

  2. Guardant360 CDx Receives CE Mark for Tumor Mutational Profiling and Tagrisso CDx Use

  3. Hologic Acquires European MDx Firm Diagenode for Approximately $159M

  4. Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year

    Premium

  5. FDA Grants Emergency Use Authorization for University of Illinois Coronavirus PCR Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.